Enzyvant Logo White Verticle

Patient Focused. Results Driven.

OUR MISSION

DEVELOP

Transformative therapies for rare diseases with high unmet needs.

PURSUE

Innovative partnerships that create new opportunities in the rare disease field.

DELIVER

On our commitment to the patients, families, and communities we serve.

OUR PIPELINE

Enzyvant Pipeline Graphic

RVT-802

Complete DiGeorge Anomaly

Children with complete DiGeorge Anomaly are born without a thymus gland, resulting in primary immunodeficiency. The disease is almost uniformly fatal within the first 24 months of life if untreated.

RVT-801

Farber Disease

Farber disease is an ultra-rare lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

July 28, 2018

Enzyvant announced today the appointments of Andrew Dawson to head human resources and Alex Tracy, PhD to lead development and manufacturing, enhancing the overall capabilities of the company

July 19, 2018

Enzyvant today announced that it has formed a collaboration with PerkinElmer Genomics, a global genomic testing company, to screen for mutations in the ASAH1 gene.

July 9, 2018

Enzyvant, announced today that it has initiated its rolling submission of a Biologics License Application (BLA) for RVT-802 to the U.S. Food and Drug Administration (FDA).

Contact us for more information.